A marker of resistance to antiplatelet therapy with aspirin and plavix

Medical Services tree

Analyzes
Genetic research
Assessment of genetic predispositions
Pharmacogenetics

A marker of resistance to antiplatelet therapy with aspirin and plavix (Selected) —
A genetic marker of the risk of adverse reactions when taking NSAIDs—
ACE inhibitors, fluvastatin, ATII receptor blockers—
Beta-blockers. The CYP2D6 gene. Pharmacogenetics—
Genetic factors of Penicillamine Effectiveness—
Genetic marker of the risk of metabolic disorders of Losartan and irbesartan—
Genetic markers of increased risk of adverse reactions when taking methotrexate—
Genetic markers of risk when taking hydralazine and procainamide—
Genetic markers of the risk of polyneuritis when taking isoniazid—
Investigation of the probability of side effects of sulfonamides—
Metabolism of irinotecan, UGT1A1—
Study of the clinical efficacy of statins—
Sulfonylurea and its derivatives: chlorpropamide, tolazamide, glibenclamide and tolbutamide—

Preparation

Специальной подготовки к исследованию не требуется.

Description

Метод определения ПЦР, секвенирование Выдаётся описание результатов врачом-генетиком.
Исследуемый материал Цельная кровь (с ЭДТА).
Генетический маркёр резистентности к антиагрегантной терапии аспирином и плавиксом. Определение наличия полиморфизма в гене тромбоцитарного рецептора фибриногена. ITGB3 (7201 и 7201A-IT).
Источник: Invitro.

✘Available only when using PRO account

Content moderator: Vasin A. S.